390 related articles for article (PubMed ID: 11755893)
1. A review of the potential role of methylnaltrexone in opioid bowel dysfunction.
Foss JF
Am J Surg; 2001 Nov; 182(5A Suppl):19S-26S. PubMed ID: 11755893
[TBL] [Abstract][Full Text] [Related]
2. Effects of intravenous methylnaltrexone on opioid-induced gut motility and transit time changes in subjects receiving chronic methadone therapy: a pilot study.
Yuan SC; Foss FJ; O'Connor M; Osinski J; Roizen FM; Moss J
Pain; 1999 Dec; 83(3):631-635. PubMed ID: 10568873
[TBL] [Abstract][Full Text] [Related]
3. A review of methylnaltrexone, a peripheral opioid receptor antagonist, and its role in opioid-induced constipation.
Shaiova L; Rim F; Friedman D; Jahdi M
Palliat Support Care; 2007 Jun; 5(2):161-6. PubMed ID: 17578067
[TBL] [Abstract][Full Text] [Related]
4. Extended-release but not immediate-release and subcutaneous methylnaltrexone antagonizes the loperamide-induced delay of whole-gut transit time in healthy subjects.
Kolbow J; Modess C; Wegner D; Oswald S; Maritz MA; Rey H; Weitschies W; Siegmund W
J Clin Pharmacol; 2016 Feb; 56(2):239-45. PubMed ID: 26313157
[TBL] [Abstract][Full Text] [Related]
5. Incidence, prevalence, and management of opioid bowel dysfunction.
Pappagallo M
Am J Surg; 2001 Nov; 182(5A Suppl):11S-18S. PubMed ID: 11755892
[TBL] [Abstract][Full Text] [Related]
6. Effects of subcutaneous methylnaltrexone on morphine-induced peripherally mediated side effects: a double-blind randomized placebo-controlled trial.
Yuan CS; Wei G; Foss JF; O'Connor M; Karrison T; Osinski J
J Pharmacol Exp Ther; 2002 Jan; 300(1):118-23. PubMed ID: 11752106
[TBL] [Abstract][Full Text] [Related]
7. Methylnaltrexone for reversal of constipation due to chronic methadone use: a randomized controlled trial.
Yuan CS; Foss JF; O'Connor M; Osinski J; Karrison T; Moss J; Roizen MF
JAMA; 2000 Jan; 283(3):367-72. PubMed ID: 10647800
[TBL] [Abstract][Full Text] [Related]
8. The safety and efficacy of oral methylnaltrexone in preventing morphine-induced delay in oral-cecal transit time.
Yuan CS; Foss JF; Osinski J; Toledano A; Roizen MF; Moss J
Clin Pharmacol Ther; 1997 Apr; 61(4):467-75. PubMed ID: 9129564
[TBL] [Abstract][Full Text] [Related]
9. Opioids and opioid receptors in the enteric nervous system: from a problem in opioid analgesia to a possible new prokinetic therapy in humans.
Holzer P
Neurosci Lett; 2004 May; 361(1-3):192-5. PubMed ID: 15135926
[TBL] [Abstract][Full Text] [Related]
10. The role of opioid receptor antagonists in the treatment of opioid-induced constipation: a review.
Leppert W
Adv Ther; 2010 Oct; 27(10):714-30. PubMed ID: 20799006
[TBL] [Abstract][Full Text] [Related]
11. Methylnaltrexone prevents morphine-induced delay in oral-cecal transit time without affecting analgesia: a double-blind randomized placebo-controlled trial.
Yuan CS; Foss JF; O'Connor M; Toledano A; Roizen MF; Moss J
Clin Pharmacol Ther; 1996 Apr; 59(4):469-75. PubMed ID: 8612393
[TBL] [Abstract][Full Text] [Related]
12. Identifying and Treating Opioid Side Effects: The Development of Methylnaltrexone.
Moss J
Anesthesiology; 2019 Jan; 130(1):142-148. PubMed ID: 30277930
[TBL] [Abstract][Full Text] [Related]
13. Use of methylnaltrexone for the treatment of opioid-induced constipation in critical care patients.
Sawh SB; Selvaraj IP; Danga A; Cotton AL; Moss J; Patel PB
Mayo Clin Proc; 2012 Mar; 87(3):255-9. PubMed ID: 22386181
[TBL] [Abstract][Full Text] [Related]
14. Clinical status of methylnaltrexone, a new agent to prevent and manage opioid-induced side effects.
Yuan CS
J Support Oncol; 2004; 2(2):111-7; discussion 119-22. PubMed ID: 15328815
[TBL] [Abstract][Full Text] [Related]
15. Methylnaltrexone Versus Naloxone for Opioid-Induced Constipation in the Medical Intensive Care Unit.
Merchan C; Altshuler D; Papadopoulos J
Ann Pharmacother; 2017 Mar; 51(3):203-208. PubMed ID: 28168885
[TBL] [Abstract][Full Text] [Related]
16. Opioid-induced bowel dysfunction: pathophysiology and potential new therapies.
Kurz A; Sessler DI
Drugs; 2003; 63(7):649-71. PubMed ID: 12656645
[TBL] [Abstract][Full Text] [Related]
17. Methylnaltrexone: a novel approach for the management of opioid-induced constipation in patients with advanced illness.
Diego L; Atayee R; Helmons P; von Gunten CF
Expert Rev Gastroenterol Hepatol; 2009 Oct; 3(5):473-85. PubMed ID: 19817669
[TBL] [Abstract][Full Text] [Related]
18. Methylnaltrexone, a novel peripheral opioid receptor antagonist for the treatment of opioid side effects.
Yuan CS; Israel RJ
Expert Opin Investig Drugs; 2006 May; 15(5):541-52. PubMed ID: 16634692
[TBL] [Abstract][Full Text] [Related]
19. Pharmacologic treatment of opioid-induced constipation.
Wang CZ; Yuan CS
Expert Opin Investig Drugs; 2013 Oct; 22(10):1225-7. PubMed ID: 23834367
[TBL] [Abstract][Full Text] [Related]
20. Methylnaltrexone: MNTX.
Drugs R D; 2006; 7(6):374-8. PubMed ID: 17073520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
